NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
5 hedge funds and large institutions have $104K invested in NLS Pharmaceutics Warrant in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
2.48% less ownership
Funds ownership: 5.5% → 3.02% (-2.5%)
29% less capital invested
Capital invested by funds: $147K → $104K (-$42.6K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $53.5K | – | -1 | -0% |
|
|
ACM
2
Altium Capital Management
New York
| $21.4K | – | – | – |
|
|
AC
3
Ayrton Capital
Westport,
Connecticut
| $18.2K | – | – | – |
|
4
Hudson Bay Capital Management
Stamford,
Connecticut
| $10.2K | – | – | – |
|
|
CS
5
Clear Street
New York
| $920 | – | – | – |
|
NLSPW Hedge Fund Activity: Q2 2023 in Review
5 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q2 2023, worth a combined $104K — down 29% from $147K a quarter earlier.
Fund positioning in NLSPW was balanced in Q2 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
- 5 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $104K of NLS Pharmaceutics Warrant stock for Q2 2023, down 29% quarter-over-quarter.
- 0 funds opened new NLS Pharmaceutics Warrant positions in Q2 2023 and 0 closed out.
Based on aggregated 13F filings for Q2 2023.